Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]
Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]
Continue reading …
Business News Today
- HDFC Bank Q3 20-21 results – Indian private lender reports 18% growth in net profit at $1.2bn
- Dr. Reddy’s Laboratories gets DCGI nod for phase 3 trial of Sputnik V vaccine
- Bharti Airtel sells stake in Loan Singh creator Seynse Technologies
- Dabur India launches Dabur 100% Pure Cow Ghee
- Infosys to acquire assets of Australian design agency Carter Digital
- ICICI Bank Niyo Bharat Payroll Card launched for MSME workers
- Huntsman wraps up $250m acquisition of Gabriel Performance Products
- Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis
- Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
- TCS rolls out Autoscape solution suite for autonomous and connected vehicle experiences
